New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 14, 2014
05:45 EDTICPTIntercept price target raised to $700 from $600 at Citigroup
Citigroup raised its price target for Intercept shares to $700 saying lipid changes in the company's FLINT trial are likely receive less regulatory scrutiny than current consensus expectations. Citi's new target reflects a higher probability of approval for the company's nonalcoholic steatohepatitis treatment and it reiterates a Buy rating on the stock.
News For ICPT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 15, 2014
08:58 EDTICPTIntercept reinstated with a Buy at BofA/Merrill
Subscribe for More Information
December 11, 2014
08:57 EDTICPTLeerink major pharma & biotech analysts hold analyst/industry conference call
Subscribe for More Information
December 5, 2014
06:06 EDTICPTIntercept announces publication of meta-analysis from Global PBC Study Group
Subscribe for More Information
December 4, 2014
10:08 EDTICPTOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:22 EDTICPTIntercept endpoint for NASH trial achievable, says Summer Street
Subscribe for More Information
06:16 EDTICPTIntercept initiated with an Outperform at RW Baird
Target $258.
December 3, 2014
11:44 EDTICPTIntercept slips after outlining possible endpoints for upcoming study
Subscribe for More Information
07:25 EDTICPTIntercept price target lowered to $99 from $125 at FBR Capital
FBR Capital lowered its price target for shares of Intercept Pharmaceuticals to $99 after the company updated guidance for the Phase III program for OCA in NASH. FBR thinks Intercept's plan to propose co-primary endpoints increases the efficacy risk of the program, especially if a lower dose is included to minimize itching and lipid excursions. The firm thinks shares are worth about $70 without the NASH opportunity. It keeps an Underperform rating on the stock.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use